SYGNIS Grants Non-exclusive License on Double Switch Technology
News Jul 23, 2015
SYGNIS AG has announced that is has signed a non-exclusive worldwide license agreement for Double Switch technology with Thermo Fisher Scientific. Financial details were not disclosed.
Under the terms of the agreement, SYGNIS AG has granted Thermo Fisher non-exclusive global rights to develop, to market and to sell products and services for the detection and analysis of protein interactions in vivo based on its proprietary Double Switch technology to researchers working in the field of proteomics.
“We are happy about the license agreement with Thermo Fisher,” SYGNIS’ CEO and CFO Pilar de la Huerta commented. “We see this agreement as a further endorsement of our Double Switch technology which addresses key needs in proteomics and drug development and are working on additional partnerships.”
SYGNIS’ Double Switch technology is based on a protease called “TEV (tobacco etch virus) protease” deriving from a plant virus. TEV protease has virtually no targets in the human proteome and therefore does not cause any damage to mammalian cells. The highly sequence specific TEV protease is a very useful tool for the analysis of protein-protein interactions as it cleaves fused proteins with simultaneous activation of a specific protein-coding.
The knowledge of signaling pathways and interactions between proteins is a key contribution for understanding molecular processes for example in basic research, in the development and progression of diseases like cancer and in drug discovery and development.
Worms Exhibit Fear and Respond to Anti-anxiety MedsNews
A team of investigators has uncovered new clues about the mechanisms of fear and anxiety through an unlikely creature: the tiny nematode worm.READ MORE
Cell Chimeras Provide Muscular Dystrophy BreakthroughNews
Fusing together healthy cells with those affected by Duchenne Muscular Dystrophy could improve muscle function.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE